NCT00531986 (MOST) is a Phase 4 clinical trial of Lopinavir-Monotherapy in HIV Infections, sponsored by Cantonal Hospital of St. Gallen.

Who is sponsoring NCT00531986?

NCT00531986 is sponsored by Cantonal Hospital of St. Gallen.

What drugs are being tested in NCT00531986?

Interventions in NCT00531986: Lopinavir-Monotherapy, HAART.

What condition does NCT00531986 study?

NCT00531986 studies HIV Infections.

Is NCT00531986 still recruiting?

NCT00531986 is currently terminated. Last updated 16 July 2018.

Last reviewed 2018-07-16 · How we verify

NCT00531986: MOST

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

HIV- Monotherapy in Switzerland (MOST- ch)

Terminated Phase 4 Last updated 16 July 2018

What this trial tests

Phase 4 trial testing Lopinavir-Monotherapy in HIV Infections in 60 participants. Terminated before completion.

Timeline

1 January 2007

Primary endpoint
1 September 2008

1 December 2008

Quick facts

Lead sponsor	Cantonal Hospital of St. Gallen
Phase	Phase 4
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	1 January 2007
Primary completion	1 September 2008
Estimated completion	1 December 2008
Sites	6 locations across Switzerland

Drugs / interventions tested

Lopinavir-Monotherapy — full drug profile →
HAART — full drug profile →

Conditions studied

HIV Infections — all drugs for HIV Infections →

Sponsor

Cantonal Hospital of St. Gallen

Who can join

18 and older, any sex, with HIV Infections. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Failure in CNS
Time frame: Week 48

Sponsor's own description

The investigators plan to conduct a two arm study, to compare failure rates in the central nervous system (CNS) and genital compartment in virologically fully suppressed patients continuing a highly active antiretroviral therapy (HAART) versus patients switching to ritonavir boosted lopinavir (Kaletra®) HIV-monotherapy. The study is composed of two phases of 48 weeks duration. In addition, neuropsychological tests (Color trial test A 1 and 2; Grooved pegboard; EWIA Digit Symbol form) and evaluation of side effects will be performed.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for HIV Infections

Currently open trials in the same condition.

NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07202546 — A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) · Phase 2 · recruiting
NCT06694753 — Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall · Phase 1 · recruiting
NCT07235852 — Pilot Testing Into the Feasibility of the Developed Cognitive Behavioral Therapy Intervention · NA · recruiting
NCT06665646 — Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Ad · Phase 1 · recruiting

Other Cantonal Hospital of St. Gallen trials

Trials by the same sponsor.

NCT07483112 — Fiber-Boost Randomized Controlled Trial · NA · recruiting
NCT06279000 — Colchicine in Patients at Cardiac Risk Undergoing Major Non-Cardiac Surgery · Phase 3 · recruiting
NCT06703814 — PROtective Ventilation With FLOW-Controlled Ventilation · NA · recruiting
NCT06256900 — Flow Controlled Ventilation in Robot-assisted Laparoscopic Surgery · NA · withdrawn
NCT06505863 — Quality of Life After Transanal Total Mesorectal Excision Compared to Traditional Total Mesorectal Excision · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00531986 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cantonal Hospital of St. Gallen
Last refreshed: 16 July 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00531986.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing